Shares of BeiGene Ltd. (HKG:6160, SHA:688235) surged nearly 7% in pre-market trading on Tuesday, after the biopharmaceutical company announced that it expects to achieve positive operating income for the full year 2025 in accordance with US GAAP (Generally Accepted Accounting Principles).
The encouraging forecast from BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative cancer medicines, sent a positive signal to investors and sparked a rally in the company's stock. Shares were up 4% in Hong Kong and 4% in Shanghai during Tuesday morning trading session.
BeiGene's projection of positive operating income for 2025 reflects the company's progress and growth prospects in the oncology market. As a leading player in the development of innovative cancer treatments, the company's strong financial performance and positive outlook have fueled investor confidence, driving the stock's upward momentum.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。